Literature DB >> 3908076

Newer methods of delivery of opiates for relief of pain.

P J Slattery, R A Boas.   

Abstract

Successful pain management using opiates requires both an analgesic with sufficient intrinsic activity and an effective administration system. Most instances of unsatisfactory pain control, however, are due to failure to achieve and maintain adequate blood concentrations of the chosen drug. Newer techniques of administration aim to overcome this problem. Oral opiate therapy with conventional or sustained-release formulations of morphine provide good control of terminal cancer pain provided that a regular dosing pattern is established and reviewed according to the patient's needs. This represents a significant departure from the traditional 'as required' prescription of this type of drug. In the management of acute severe pain, sublingual and intravenous opiates--self-administered as needed, or given by mandatory dosing schedules--have also been shown to overcome the limitations of intermittent intramuscular injections. A further novel development, stemming from basic neuroscience research, is the selective application of opiates to the spinal cord via the epidural or intrathecal route. This controversial technique has led to major improvements in treatment of some types of acute and chronic pain.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3908076     DOI: 10.2165/00003495-198530060-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  57 in total

1.  Pharmacokinetic aspects of optimal pain treatment.

Authors:  L K Paalzow
Journal:  Acta Anaesthesiol Scand Suppl       Date:  1982

2.  Single injection spinal anaesthesia with amethocaine and morphine for transurethral prostatectomy.

Authors:  A J Cunningham; J A McKenna; D S Skene
Journal:  Br J Anaesth       Date:  1983-05       Impact factor: 9.166

3.  The Brompton mixture versus morphine solution given orally: effects on pain.

Authors:  R Melzack; B M Mount; J M Gordon
Journal:  Can Med Assoc J       Date:  1979-02-17       Impact factor: 8.262

4.  Patient-controlled analgesic therapy, Part II: Individual analgesic demand and analgesic plasma concentrations of pethidine in postoperative pain.

Authors:  A Tamsen; P Hartvig; C Fagerlund; B Dahlström
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

5.  Pain relief after abdominal surgery--a comparison of i.m. morphine, sublingual buprenorphine and self-administered i.v. pethidine.

Authors:  R Ellis; D Haines; R Shah; B R Cotton; G Smith
Journal:  Br J Anaesth       Date:  1982-04       Impact factor: 9.166

6.  Multiple intramuscular injections: a major source of variability in analgesic response to meperidine.

Authors:  K L Austin; J V Stapleton; L E Mather
Journal:  Pain       Date:  1980-02       Impact factor: 6.961

7.  Pharmacokinetic aspects of intrathecal morphine analgesia.

Authors:  G Nordberg; T Hedner; T Mellstrand; B Dahlström
Journal:  Anesthesiology       Date:  1984-05       Impact factor: 7.892

8.  Clinical effects of buprenorphine during and after operation.

Authors:  H J McQuay; R E Bullingham; G M Paterson; R A Moore
Journal:  Br J Anaesth       Date:  1980-10       Impact factor: 9.166

9.  [3H]Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord.

Authors:  J E Leysen; W Gommeren; C J Niemegeers
Journal:  Eur J Pharmacol       Date:  1983-02-18       Impact factor: 4.432

10.  The minimum effective analgetic blood concentration of pethidine in patients with intractable pain.

Authors:  L E Mather; C J Glynn
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

View more
  1 in total

1.  Development of a GC-MS assay for the determination of fentanyl pharmacokinetics in rabbit plasma after sublingual spray delivery.

Authors:  Ahmad H Malkawi; Abeer M Al-Ghananeem; Peter A Crooks
Journal:  AAPS J       Date:  2008-05-06       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.